Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

ASCENDIS PHARMA A/S

(ASND)
  Report
Delayed Nasdaq  -  04:00 2022-09-30 pm EDT
103.26 USD   +0.62%
09/29Ascendis Pharma Added to Wedbush Best Ideas List
MT
09/22European ADRs Move Lower in Thursday Trading
MT
09/22Wells Fargo Adjusts Ascendis Pharma Price Target to $172 From $167, Maintains Overweight Rating
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Transcript : Ascendis Pharma A/S, Q2 2022 Earnings Call, Aug 10, 2022

08/10/2022 | 04:30pm EDT
Good day, and thank you for standing by. Welcome to the Ascendis Pharma Second Quarter 2022 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being...


ę S&P Capital IQ 2022
All news about ASCENDIS PHARMA A/S
09/29Ascendis Pharma Added to Wedbush Best Ideas List
MT
09/22European ADRs Move Lower in Thursday Trading
MT
09/22Wells Fargo Adjusts Ascendis Pharma Price Target to $172 From $167, Maintains Overweigh..
MT
09/14Ascendis Pharma A/s : Articles of Association - Form 6-K
PU
09/13Transcript : Ascendis Pharma A/S Presents at Morgan Stanley 20th Annual Globa..
CI
09/12Ascendis Pharma A/S Appoints William Carl Fairey Jr. and Siham Imani as Class I Directo..
CI
09/12New Long-Term Data in Adult Patients with Hypoparathyroidism Treated with Ascendis Phar..
AQ
09/12Ascendis Pharma A/S announces new Week 110 data from the Phase 2 PaTH Forward Trial
CI
09/08European ADRs Move Slightly Higher in Thursday Trading
MT
09/07Transcript : Ascendis Pharma A/S Presents at Citi's 17th Annual BioPharma Con..
CI
More news
Analyst Recommendations on ASCENDIS PHARMA A/S
More recommendations
Financials
Sales 2022 34,8 M 34,1 M 34,1 M
Net income 2022 -500 M -490 M -490 M
Net cash 2022 620 M 608 M 608 M
P/E ratio 2022 -11,7x
Yield 2022 -
Capitalization 5 882 M 5 768 M 5 768 M
EV / Sales 2022 151x
EV / Sales 2023 40,9x
Nbr of Employees 639
Free-Float 10,3%
Chart ASCENDIS PHARMA A/S
Duration : Period :
Ascendis Pharma A/S Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ASCENDIS PHARMA A/S
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 14
Last Close Price 105,30 €
Average target price 146,14 €
Spread / Average Target 38,8%
EPS Revisions
Managers and Directors
Jan M°ller Mikkelsen President, CEO & Executive Director
Scott Thomas Smith Chief Financial Officer & Senior Vice President
Albert Cha Chairman
Birgitte Volck SVP, Head-Clinical Development & Medical Affairs
Kennett Sprog°e Senior Vice President, Head-Innovation & Research
Sector and Competitors
1st jan.Capi. (M$)
ASCENDIS PHARMA A/S-23.24%5 768
GILEAD SCIENCES, INC.-15.04%77 320
VERTEX PHARMACEUTICALS31.85%74 255
REGENERON PHARMACEUTICALS, INC.9.08%73 646
BIONTECH SE-47.68%32 778
WUXI APPTEC CO., LTD.-39.54%29 043